Efficacy and Safety of Madalena Association in the Treatment of Type II Diabetes Mellitus
Study Details
Design, interventions, and primary outcomes
About This Study
The purpose of this study is to evaluate the efficacy and safety of Madalena association in the treatment of type 2 diabetes mellitus.
Design
Interventions / Regimen
- Drug: MADALENA ASSOCIATION — Madalena association coated tablet.
- Drug: METFORMIN — Metformin 1000 mg extended-release tablet.
- Drug: EMPAGLIFLOZIN + LINAGLIPTIN — Empagliflozin 10 mg + linagliptin 5 mg coated tablet.
- Other: MADALENA ASSOCIATION PLACEBO — Madalena association placebo tablet.
- Other: METFORMIN PLACEBO — Metformin placebo tablet.
- Other: EMPAGLIFLOZIN + LINAGLIPTIN PLACEBO — Empagliflozin + linagliptin placebo tablet.
Primary Outcomes
- Change from baseline in glycated hemoglobin (HbA1c) levels. (120 days)
Phase: PHASE3
Status: Recruiting
Start Date: 2024-11-18
Completion: 2027-06
Sex: ALL
Volunteers: false
Enrollment: 270 (ESTIMATED)
- Drug: MADALENA ASSOCIATION — Madalena association coated tablet.
- Drug: METFORMIN — Metformin 1000 mg extended-release tablet.
- Drug: EMPAGLIFLOZIN + LINAGLIPTIN — Empagliflozin 10 mg + linagliptin 5 mg coated tablet.
- Other: MADALENA ASSOCIATION PLACEBO — Madalena association placebo tablet.
- Other: METFORMIN PLACEBO — Metformin placebo tablet.